Blog
Featured post
Truveta Data now includes more than 120 million de-identified patients
Truveta has also partnered with more than 100 organizations across life sciences, healthcare, public health, academic research organizations, and others to use regulatory-grade EHR data enabling scientifically rigorous research.
A journey into rare disease research
Rare diseases as a category aren’t that rare if you consider they impact 30 million Americans and 400 million people around the world. Not to mention their families, who often...
New research uses Truveta Data to study treatment for hospitalized pregnant patients with COVID-19
Scientists from the Institute for Systems Biology (ISB) have published new research in the JMIR Public Health and Surveillance journal. The work explores the National Institute...
How expert-led AI is powering data-driven insights on less common conditions
Using real-world data to understand a patient’s journey through the healthcare ecosystem can be challenging, particularly for rare or less common diseases. The relevant data are...
Real-time monitoring of prescription trends and demographics of two SGLT2i drugs
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin...
Unlocking real-world data for cardiovascular research: The promise of complete and clean EHR data for drug and device development
The Centers for Disease Control and Prevention reports that cardiovascular (CV) disease is the leading cause of death for men, women, and people of most racial and ethnic groups...
Building a learning public health system
I can’t imagine our country without the FDA continuously assessing the safety and efficacy of medical products, or our government without the CDC monitoring and guiding public...
Alzheimer’s disease research: A new era
We are entering a new era of Alzheimer’s Disease research. Researchers from the University of Tsukuba in Japan along with IBM Research have recently developed a mobile app to...
Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have...
A pragmatic suggestion for medical AI regulation
There is a growing global consensus that “we need to regulate AI”. The most commonly cited suggestion is that we create a new global government agency to issue licenses for...